Aristides Capital LLC Invests $567,000 in Moderna, Inc. $MRNA

Key Points

• Aristides Capital LLC has acquired a new stake in Moderna, purchasing 20,000 shares worth approximately $567,000 in the 1st quarter.
• Moderna's shares have experienced a decline of 6.5%, opening at $25.35 with a market cap of $9.86 billion.
• Analysts provide mixed ratings for Moderna, with a consensus price target of $42.88 and an average rating of "Hold".

Aristides Capital LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 20,000 shares of the company's stock, valued at approximately $567,000.

Other institutional investors have also added to or reduced their stakes in the company. S Bank Fund Management Ltd bought a new stake in shares of Moderna during the first quarter valued at approximately $25,000. SVB Wealth LLC bought a new stake in shares of Moderna during the first quarter valued at approximately $28,000. Itau Unibanco Holding S.A. raised its stake in shares of Moderna by 51.2% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares in the last quarter. Costello Asset Management INC bought a new stake in shares of Moderna during the first quarter valued at approximately $30,000. Finally, Vega Investment Solutions bought a new stake in shares of Moderna during the fourth quarter valued at approximately $45,000. Institutional investors own 75.33% of the company's stock.

Analysts Set New Price Targets

MRNA has been the subject of several research analyst reports. Citigroup initiated coverage on shares of Moderna in a research note on Friday, August 1st. They set a "neutral" rating and a $40.00 price target for the company. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Cowen initiated coverage on shares of Moderna in a research note on Sunday, July 13th. They set a "hold" rating for the company. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research note on Friday, August 1st. Finally, Evercore ISI set a $32.00 price target on shares of Moderna in a research note on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, Moderna presently has an average rating of "Hold" and a consensus price target of $42.88.

Moderna Stock Performance

NASDAQ:MRNA traded down $0.38 during trading hours on Friday, reaching $24.09. The company's stock had a trading volume of 8,273,275 shares, compared to its average volume of 9,437,135. The company has a market capitalization of $9.37 billion, a P/E ratio of -3.20 and a beta of 1.83. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $79.96. The stock has a 50 day moving average price of $29.09 and a two-hundred day moving average price of $28.85.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna's revenue for the quarter was down 41.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.